Galmed Pharmaceuticals ( (GLMD) ) has provided an update.
On April 17, 2025, Galmed Pharmaceuticals announced a collaboration with Virginia Commonwealth University to study Aramchol’s potential in overcoming drug resistance in gastrointestinal cancers. This strategic move marks Galmed’s expansion into oncology, leveraging Aramchol’s novel mechanism to potentially enhance the efficacy of existing cancer treatments. The collaboration aims to address the high mortality rates and limited treatment options for colorectal and liver cancers by exploring Aramchol’s ability to reverse therapy resistance. This initiative could significantly impact Galmed’s market positioning by broadening its therapeutic applications and offering a promising new approach to cancer treatment.
Spark’s Take on GLMD Stock
According to Spark, TipRanks’ AI Analyst, GLMD is a Underperform.
Galmed Pharmaceuticals faces significant financial challenges with no revenue and continuous operational losses. The technical indicators signal a strong bearish trend, and the valuation metrics highlight ongoing unprofitability with a negative P/E ratio. Despite a debt-free balance sheet, the company’s reliance on equity financing amid operational inefficiencies poses substantial risks.
To see Spark’s full report on GLMD stock, click here.
More about Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on developing Aramchol, primarily targeting liver diseases such as NASH and fibrosis. The company is expanding its pipeline to include oncological indications, specifically targeting drug resistance in gastrointestinal cancers. Galmed is also exploring opportunities in cardiometabolic indications and other innovative therapies.
YTD Price Performance: -59.04%
Average Trading Volume: 891,265
Technical Sentiment Signal: Buy
Current Market Cap: $3.18M
Find detailed analytics on GLMD stock on TipRanks’ Stock Analysis page.